CoChat

No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials

Open access
Al-Gobari, Muaamar, Le, Hai-Ha, Fall, Mor, Gueyffier, François, Burnand, Bernard · 2017 · PLOS ONE

The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Statins showed mixed results in heart failure (HF) patients. The benefits in major HF outcomes, including all-cause mortality and sudden cardiac death (SCD), have always been discordant across systematic reviews and meta-analyses. We intended to systematically identify and appraise the available evidence that evaluated the effectiveness of statins in clinical outcomes for HF patients. DESIGN: Systematic review and meta-analysis. DATA SOURCES: We searched, until April 28, 2016: Medline, Embase, ISI Web of Science and EBM reviews (Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED), checked clinicaltrials.gov for ongoing trials and manually searched references of included studies. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We identified 24 randomized clinical trials that evaluated the efficacy of statins for HF patients. All randomized clinical trials were assessed for risk of bias and pooled together in a meta-analysis. Pre-specified outcomes were sudden cardiac death, all-cause mortality, and hospitalization for worsening heart failure. RESULTS: Statins did not reduce sudden cardiac death (SCD) events in HF patients [relative risk (RR) 0.92, 95% confidence interval (CI) 0.70 to 1.21], all-cause mortality [RR 0.88, 95% CI 0.75 to 1.02] but significantly reduced hospitalization for worsening heart failure (HWHF) although modestly [RR 0.79, 95% CI 0.66 to 0.94]. Nevertheless, estimated predictive intervals were insignificant in SCD, all-cause mortality and HWHF [RR, 0.54 to 1.63, 0.64 to 1.19, and 0.54 to 1.15], respectively. An important finding was the possible presence of publication bias, small-study effects and heterogeneity of the trials conducted in HF patients. CONCLUSIONS: Statins do not reduce sudden cardiac death, all-cause mortality, but may slightly decrease hospitalization for worsening heart failure in HF patients. The evaluation of the risk of biases suggested moderate quality of the published results. Until new evidence is available, this study supports the 2013 ACCF/AHA guidelines to not systematically prescribe statins in "only" HF patients, which should help avoid unnecessary polypharmacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0171168

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flow chart for search result.
Fig 1 Flow chart for search result.CC BY · PubMed Central
Fig 2 Risk of bias for included studies. A) Risk of bias graph for statin trials in heart failure patients: review authors' judgments about each risk of bias item presented as percentages across all included studies. B) Risk of bias summary for statins in heart failure patients: review authors' judgments about each risk of bias item for each included study.
Fig 2 Risk of bias for included studies. A) Risk of bias graph for statin trials in heart failure patients: review authors' judgments about each risk of bias item presented as percentages across all included studies. B) Risk of bias summary for statins in heart failure patients: review authors' judgments about each risk of bias item for each included study.CC BY · PubMed Central
Fig 3 GRADE summary of findings table.
Fig 3 GRADE summary of findings table.CC BY · PubMed Central
Fig 4 Efficacy of statins compared with control in heart failure for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).
Fig 4 Efficacy of statins compared with control in heart failure for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).CC BY · PubMed Central
Fig 5 Efficacy of statins compared with control in heart failure stratified by follow-up duration for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).
Fig 5 Efficacy of statins compared with control in heart failure stratified by follow-up duration for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).CC BY · PubMed Central
Fig 6 Sensitivity analysis without corona and GISSI-HF.
Fig 6 Sensitivity analysis without corona and GISSI-HF.CC BY · PubMed Central
Fig 7 Sensitivity analysis without less powered studies.
Fig 7 Sensitivity analysis without less powered studies.CC BY · PubMed Central
Fig 8 Efficacy of statins compared with control in heart failure stratified by sample size (more than 100 or less than 100) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).
Fig 8 Efficacy of statins compared with control in heart failure stratified by sample size (more than 100 or less than 100) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).CC BY · PubMed Central
Fig 9 Efficacy of statins compared with control in heart failure stratified by population type (ischaemic or non-ischaemic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).
Fig 9 Efficacy of statins compared with control in heart failure stratified by population type (ischaemic or non-ischaemic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).CC BY · PubMed Central
Fig 10 Efficacy of statins compared with control in heart failure stratified by endpoint (those with against without mortality and/or HWHF) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF). [Random-effects model].
Fig 10 Efficacy of statins compared with control in heart failure stratified by endpoint (those with against without mortality and/or HWHF) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF). [Random-effects model].CC BY · PubMed Central
Fig 11 Funnel plots of SE (log odds ratio) by odds ratio to evaluate publication bias for the effect of treatment for prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF). (Fixed-effects model).
Fig 11 Funnel plots of SE (log odds ratio) by odds ratio to evaluate publication bias for the effect of treatment for prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF). (Fixed-effects model).CC BY · PubMed Central
Fig 12 Efficacy of statins compared with control in heart failure stratified by statin type (lipophilic versus hydrophilic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).
Fig 12 Efficacy of statins compared with control in heart failure stratified by statin type (lipophilic versus hydrophilic) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 2

  1. MJ Lipinski, 2009, Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure, American Journal of Cardiology, 104, 1708, 10.1016/j.amjcard.2009.07.055 · DOI
  2. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination; c2014. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure; 2009 [cited 2016 Jun 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0027479/.

Cited by

See all 38

Metadata

Authors
Al-Gobari, M., Le, H.-H., Fall, M., Gueyffier, F., & Burnand, B.
Affiliations
  • Lyon 1 Université (FR)
  • Centre Hospitalier Universitaire Vaudois (CH)
Venue
PLOS ONE
Published
2017-02-06
Volume
12
Issue
2
Pages
e0171168
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2586344441
Cited by
38
References
70
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 7 · 2018: 2 · 2017: 3
FWCI
0.58
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Funders
  • Staatssekretariat für Bildung, Forschung und Innovation (2014.0193)
  • Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
statins, heart failure, reduced ejection fraction, sudden cardiac death, all-cause mortality, hospitalization for worsening heart failure, risk of bias, publication bias, small-study effects, trial heterogeneity, cardiovascular risk stratification, secondary prevention, LDL cholesterol lowering, statin tolerability
MeSH terms
Cause of Death, Heart Failure, Humans, Stroke Volume, Odds Ratio, Randomized Controlled Trials as Topic, Death, Sudden, Cardiac, Treatment Outcome, Publication Bias, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1371/journal.pone.0171168
The paper
Al-Gobari, M., Le, H.-H., Fall, M., Gueyffier, F., & Burnand, B. (2017). No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials. PLOS ONE. https://doi.org/10.1371/journal.pone.0171168

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.